US9895380B2ActiveUtilityA1

Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection

80
Assignee: INST NAT SANTE RECH MEDPriority: Sep 11, 2013Filed: Sep 10, 2014Granted: Feb 20, 2018
Est. expirySep 11, 2033(~7.2 yrs left)· nominal 20-yr term from priority
Inventors:Patrice AndreVincent LotteauPauline RadreauMarine GilardoneAmaury PatinDidier RocheDaniel CravoSophie Hallakou-Bozec
A61P 43/00A61P 31/20A61P 1/16A61P 1/00A61K 31/551A61K 31/42A61K 31/55A61K 31/496A61K 31/522A61K 31/4525A61K 31/513A61K 38/212A61K 31/675A61K 31/7072A61K 45/06A61K 31/575A61K 2300/00
80
PatentIndex Score
5
Cited by
14
References
9
Claims

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. A method for reducing hepatitis B virus (HBV) replication in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a farnesoid X receptor (FXR) antagonist. 
     
     
       2. The method of  claim 1 , wherein the subject is infected with a hepatitis B virus genotype selected from A, B, C, and D. 
     
     
       3. The method of  claim 1 , wherein the subject has a chronic HBV infection. 
     
     
       4. The method of  claim 1 , wherein the farnesoid X receptor (FXR) agonist is a selective FXR agonist. 
     
     
       5. The method of  claim 1 , wherein the farnesoid X receptor (FXR) agonist is selected from the group consisting of the compounds identified by the CAS REGISTRY NUMBERS 1192171-69-9, 6ECDCA, GW4064, PXL0914, and PXL0743. 
     
     
       6. The method of  claim 1 , wherein the farnesoid X receptor (FXR) agonist is selected from the group consisting of the compounds identified by the CAS REGISTRY NUMBERS 1192171-69-9 and 6ECDCA. 
     
     
       7. The method of  claim 1 , wherein the subject has failed to respond to a previous treatment for HBV infection. 
     
     
       8. The method of  claim 7 , wherein the previous treatment is selected from the group consisting of lamivudine (Epivir), adefovir (Hepsera), tenofovir (Viread), telbivudine (Tyzeka), entecavir (Baraclude), interferon alpha-2a, PEGylated interferon alpha-2a (Pegasys) and interferon alpha-2b (ViraferonPeg or Introna). 
     
     
       9. The method of  claim 1 , wherein the FXR agonist is administered in combination with a treatment selected from the group consisting of lamivudine (Epivir), adefovir (Hepsera), tenofovir (Viread), telbivudine (Tyzeka), entecavir (Baraclude), interferon alpha-2a, PEGylated interferon alpha-2a (Pegasys) and interferon alpha-2b (ViraferonPeg or Introna).

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.